Dual Anti-Mesothelin/Anti-Alpha-Folate Receptor CAR T-Cell Therapy (University of Pennsylvania)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameDual Anti-Mesothelin/Anti-Alpha-Folate Receptor CAR T-Cell Therapy (University of Pennsylvania)
Drug Alias NameDual Anti-Alpha-Folate Receptor/Anti-Mesothelin CAR T-Cell Therapy (University of Pennsylvania)Dual Anti-Mesothelin/Anti-Alpha-Folate Receptor Chimeric Antigen Receptor T-Lymphocyte Therapy (University of Pennsylvania)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionFolate receptor alpha modulatorsMesothelin modulators
TargetsFolate receptor alphaMesothelin
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Pennsylvania
Active IndicationsN/A
Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A